TY - JOUR
T1 - Host-pathogen interaction in COVID-19
T2 - Pathogenesis, potential therapeutics and vaccination strategies
AU - Varghese, Praveen Mathews
AU - Tsolaki, Anthony G.
AU - Yasmin, Hadida
AU - Shastri, Abhishek
AU - Ferluga, Janez
AU - Vatish, Manu
AU - Madan, Taruna
AU - Kishore, Uday
N1 - Publisher Copyright:
© 2020 Elsevier GmbH
PY - 2020/11
Y1 - 2020/11
N2 - The current coronavirus pandemic, COVID-19, is the third outbreak of disease caused by the coronavirus family, after Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome. It is an acute infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This severe disease is characterised by acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation dysfunction, and multiple organ dysfunction syndromes. Currently, no drugs or vaccines exist against the disease and the only course of treatment is symptom management involving mechanical ventilation, immune suppressants, and repurposed drugs. The severe form of the disease has a relatively high mortality rate. The last six months have seen an explosion of information related to the host receptors, virus transmission, virus structure-function relationships, pathophysiology, co-morbidities, immune response, treatment and the most promising vaccines. This review takes a critically comprehensive look at various aspects of the host-pathogen interaction in COVID-19. We examine the genomic aspects of SARS-CoV-2, modulation of innate and adaptive immunity, complement-triggered microangiopathy, and host transmission modalities. We also examine its pathophysiological impact during pregnancy, in addition to emphasizing various gaps in our knowledge. The lessons learnt from various clinical trials involving repurposed drugs have been summarised. We also highlight the rationale and likely success of the most promising vaccine candidates.
AB - The current coronavirus pandemic, COVID-19, is the third outbreak of disease caused by the coronavirus family, after Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome. It is an acute infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This severe disease is characterised by acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation dysfunction, and multiple organ dysfunction syndromes. Currently, no drugs or vaccines exist against the disease and the only course of treatment is symptom management involving mechanical ventilation, immune suppressants, and repurposed drugs. The severe form of the disease has a relatively high mortality rate. The last six months have seen an explosion of information related to the host receptors, virus transmission, virus structure-function relationships, pathophysiology, co-morbidities, immune response, treatment and the most promising vaccines. This review takes a critically comprehensive look at various aspects of the host-pathogen interaction in COVID-19. We examine the genomic aspects of SARS-CoV-2, modulation of innate and adaptive immunity, complement-triggered microangiopathy, and host transmission modalities. We also examine its pathophysiological impact during pregnancy, in addition to emphasizing various gaps in our knowledge. The lessons learnt from various clinical trials involving repurposed drugs have been summarised. We also highlight the rationale and likely success of the most promising vaccine candidates.
KW - Anti-virals
KW - Co-morbidities
KW - COVID-19
KW - Life-cycle
KW - Pathophysiology
KW - Pregnancy
KW - SARS-CoV-2
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85094592079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094592079&partnerID=8YFLogxK
U2 - 10.1016/j.imbio.2020.152008
DO - 10.1016/j.imbio.2020.152008
M3 - Review article
C2 - 33130519
AN - SCOPUS:85094592079
SN - 0171-2985
VL - 225
JO - Immunobiology
JF - Immunobiology
IS - 6
M1 - 152008
ER -